TMU Implements Watson for Oncology

News Announcements
Poster:ylin59Post date:2017-07-19
Taipei Medical University Implements Watson for Oncology to Help Oncologists Make Evidence-Based Cancer Treatment Decisions

Taipei Medical University is the first healthcare system in Taiwan to adopt Watson for Oncology


Taipei, TaiwanJul 14, 2017: Taipei Medical University today announced that it will adopt IBM Watson for Oncology trained by Memorial Sloan Kettering (MSK). Taipei Medical University Healthcare Systems includes five affiliated hospitals, TMU Hospital, Wan Fang Hospital, Shuang Ho Hospital, Taipei Cancer Center, and LiHuiLi Eastern Hospital. It has a combined capacity of more than 3,000 beds and is the largest healthcare system in metropolitan Taipei. Watson for Oncology went live at Taipei Medical University Healthcare Systems in June.


In Taiwan, it is estimated that there will be more than 100,000 new cancer cases this year.(1) As healthcare providers and systems seek to enable data-driven, evidence-based cancer care, an explosion of medical information has created both challenges and opportunities to improve quality care. Currently, approximately 50,000 oncology research papers are published annually,(2) and by 2020 medical information is projected to double every 73 days(3), outpacing the ability of humans to keep up with the proliferation of medical knowledge.


Watson for Oncology identifies treatment options with supporting medical evidence for consideration by the treating oncologist, drawing from more than 300 medical journals, more than 200 textbooks, and nearly 15 million pages of text to provide insights about different treatment options and also provides oncologists with information regarding drug treatment options. Watson also ranks the evidence-based treatment options, linking to peer reviewed studies and clinical guidelines.


“The introduction of Watson for Oncology will be a game changer for cancer patients in Taiwan,” said President Yun Yen, Taipei Medical University, who is also a renowned oncologist and translational researcher. “With Watson, our team of oncologists can make informed treatment decisions for patients based on insights derived from the individuals’ unique health status, the latest medical research and other relevant data.”


A growing body of data suggests the value of Watson in cancer care, for example:

·         A 2017 study found Watson for Oncology matched clinicians’ treatment recommendations in up to 96% of cases.

·         A 2015 study discusses use of Watson for Oncology on clinical cases at MSK.

·         A 2014 study discusses the latest developments in Watson for Oncology training to achieve up to 100% concordance with MSK physicians.


“Our goal with Watson for Oncology is to democratize access to the growing body of cancer knowledge available today,” said Rob Merkel, vice president of oncology and genomics, IBM Watson Health. “Watson cultivates actionable information based on that data at the point of care for the treating oncologist and we are proud to be working with leading organizations like Taipei Medical University Healthcare Systems to put this cognitive computing tool into the hands of physicians worldwide.”



[1] Taiwan Cancer Registry, Health Promotion Administration (HPA), Ministry of Health and Welfare, Taiwan

[2] PubMed, accessed at pubmed.com

[3] Densen, Peter, Challenges and Opportunities Facing Medical Education 2011. Transactions in the American Clinical and Climatological Association. Accessed at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3116346/



Last modification time:2017-07-20 AM 7:12

    cron web_use_log